NCT05714839 - A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

December 3, 2029

Study Completion Date

December 3, 2029

Conditions

Multiple Myeloma

Interventions

DRUG

Belantamab

Belantamab will be administered.

DRUG

Belantamab mafodotin

Belantamab mafodotin will be administered.

DRUG

Belantamab and belantamab mafodotin

Belantamab and belantamab mafodotin used in combination (delivered as separate drugs) will be administered.

Trial Locations (21)

100

RECRUITING

GSK Investigational Site, Taipei

500

RECRUITING

GSK Investigational Site, Changhua

3065

RECRUITING

GSK Investigational Site, Fitzroy

6009

COMPLETED

GSK Investigational Site, Nedlands

49546

RECRUITING

GSK Investigational Site, Grand Rapids

B1702

COMPLETED

GSK Investigational Site, Ciudadela

R8500ACE

RECRUITING

GSK Investigational Site, Viedma

89201-260

RECRUITING

GSK Investigational Site, Joinville

41253-190

RECRUITING

GSK Investigational Site, Salvador

04537-080

RECRUITING

GSK Investigational Site, São Paulo

030-8553

RECRUITING

GSK Investigational Site, Aomori

277-8577

RECRUITING

GSK Investigational Site, Chiba

545-8586

COMPLETED

GSK Investigational Site, Osaka

105-8471

RECRUITING

GSK Investigational Site, Tokyo

80-214

WITHDRAWN

GSK Investigational Site, Gdansk

20-081

RECRUITING

GSK Investigational Site, Lublin

137-701

RECRUITING

GSK Investigational Site, Seoul

138-736

RECRUITING

GSK Investigational Site, Seoul

LE1 5WW

RECRUITING

GSK Investigational Site, Leicester

OX3 7LE

RECRUITING

GSK Investigational Site, Oxford

PL6 8DH

RECRUITING

GSK Investigational Site, Plymouth